The latest price target for MariMed (OTCQB:MRMD) was reported by Zuanic & Associates on November 6, 2023. The analyst firm set a price target for $0.00 expecting MRMD to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for MariMed (OTCQB:MRMD) was provided by Zuanic & Associates, and MariMed initiated their overweight rating.

There is no last upgrade for MariMed

There is no last downgrade for MariMed.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MariMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MariMed was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.

While ratings are subjective and will change, the latest MariMed (MRMD) rating was a initiated with a price target of $0.00 to $0.00. The current price MariMed (MRMD) is trading at is $0.07, which is out of the analyst’s predicted range.